Pascale Fouqueray

1.6k total citations
28 papers, 1.2k citations indexed

About

Pascale Fouqueray is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Pascale Fouqueray has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Molecular Biology and 14 papers in Surgery. Recurrent topics in Pascale Fouqueray's work include Diabetes Treatment and Management (16 papers), Metabolism, Diabetes, and Cancer (14 papers) and Pancreatic function and diabetes (13 papers). Pascale Fouqueray is often cited by papers focused on Diabetes Treatment and Management (16 papers), Metabolism, Diabetes, and Cancer (14 papers) and Pancreatic function and diabetes (13 papers). Pascale Fouqueray collaborates with scholars based in France, United States and Japan. Pascale Fouqueray's co-authors include Sébastien Bolze, Sophie Hallakou‐Bozec, Julie Dubourg, Valdis Pīrāgs, Harold E. Lebovitz, Jean‐Marie Grouin, Éric Fontaine, David E. Moller, Guillaume Vial and Micheline Kergoat and has published in prestigious journals such as PLoS ONE, Diabetes Care and European Heart Journal.

In The Last Decade

Pascale Fouqueray

28 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pascale Fouqueray France 19 745 694 575 220 144 28 1.2k
Sébastien Bolze France 16 504 0.7× 573 0.8× 414 0.7× 247 1.1× 151 1.0× 25 1.0k
Sophie Hallakou‐Bozec France 17 429 0.6× 513 0.7× 369 0.6× 242 1.1× 150 1.0× 22 920
Masanori Yokono Japan 10 717 1.0× 401 0.6× 418 0.7× 220 1.0× 109 0.8× 17 970
Rumi Kihara Japan 9 540 0.7× 342 0.5× 319 0.6× 189 0.9× 74 0.5× 12 791
Danielle Duffy United States 17 465 0.6× 326 0.5× 587 1.0× 130 0.6× 94 0.7× 42 1.2k
Jane Pinaire United States 15 650 0.9× 743 1.1× 263 0.5× 266 1.2× 152 1.1× 21 1.3k
G Lübben Germany 20 851 1.1× 717 1.0× 370 0.6× 346 1.6× 203 1.4× 40 1.6k
Moira A. Clay Australia 14 554 0.7× 283 0.4× 592 1.0× 139 0.6× 113 0.8× 19 1.1k
Hongwen Zhou China 18 210 0.3× 660 1.0× 378 0.7× 185 0.8× 228 1.6× 61 1.2k
Richard L. Dunbar United States 18 587 0.8× 308 0.4× 664 1.2× 197 0.9× 146 1.0× 52 1.4k

Countries citing papers authored by Pascale Fouqueray

Since Specialization
Citations

This map shows the geographic impact of Pascale Fouqueray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascale Fouqueray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascale Fouqueray more than expected).

Fields of papers citing papers by Pascale Fouqueray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascale Fouqueray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascale Fouqueray. The network helps show where Pascale Fouqueray may publish in the future.

Co-authorship network of co-authors of Pascale Fouqueray

This figure shows the co-authorship network connecting the top 25 collaborators of Pascale Fouqueray. A scholar is included among the top collaborators of Pascale Fouqueray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascale Fouqueray. Pascale Fouqueray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrison, Stephen A., Sébastien Bolze, Sheila H. DeWitt, et al.. (2023). Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). Journal of Hepatology. 78(5). 914–925. 47 indexed citations
2.
Fouqueray, Pascale, et al.. (2023). Imeglimin: A Clinical Pharmacology Review. Clinical Pharmacokinetics. 62(10). 1393–1411. 3 indexed citations
3.
Fouqueray, Pascale, et al.. (2022). Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects. Clinical Drug Investigation. 42(9). 721–732. 14 indexed citations
4.
Theurey, Pierre, Valdis Pīrāgs, Andrea Mari, et al.. (2022). Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity. Endocrinology Diabetes & Metabolism. 5(6). e371–e371. 19 indexed citations
5.
Hallakou‐Bozec, Sophie, Micheline Kergoat, Pascale Fouqueray, Sébastien Bolze, & David E. Moller. (2021). Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE. 16(2). e0241651–e0241651. 59 indexed citations
6.
Fouqueray, Pascale, Sébastien Bolze, Julie Dubourg, et al.. (2021). Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. Cell Reports Medicine. 2(12). 100474–100474. 34 indexed citations
7.
8.
9.
Cusi, Kenneth, Naim Alkhouri, Stephen A. Harrison, et al.. (2021). Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. ˜The œLancet. Gastroenterology & hepatology. 6(11). 889–902. 50 indexed citations
10.
Hallakou‐Bozec, Sophie, Guillaume Vial, Micheline Kergoat, et al.. (2020). Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obesity and Metabolism. 23(3). 664–673. 127 indexed citations
11.
Dubourg, Julie, et al.. (2020). Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. European Journal of Clinical Pharmacology. 76(10). 1393–1400. 13 indexed citations
12.
Fouqueray, Pascale, et al.. (2020). Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. Clinical Pharmacokinetics. 59(10). 1261–1271. 15 indexed citations
13.
Dubourg, Julie, et al.. (2020). Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment. Clinical Pharmacokinetics. 60(4). 485–490. 11 indexed citations
14.
Fouqueray, Pascale, et al.. (2020). In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans. Drug Metabolism and Disposition. 48(12). 1330–1346. 29 indexed citations
15.
Dubourg, Julie, et al.. (2020). Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 45(6). 725–733. 12 indexed citations
16.
Détaille, Dominique, Guillaume Vial, Anne‐Laure Borel, et al.. (2016). Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discovery. 2(1). 15072–15072. 75 indexed citations
17.
Wagner, Franz F., J. Vogt, Ulrich Wachter, et al.. (2012). Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock. Critical Care. 16(S1). 8 indexed citations
18.
Pīrāgs, Valdis, Harold E. Lebovitz, & Pascale Fouqueray. (2012). Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obesity and Metabolism. 14(9). 852–858. 102 indexed citations
19.
Fouqueray, Pascale, Valdis Pīrāgs, Silvio E. Inzucchi, et al.. (2012). The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care. 36(3). 565–568. 80 indexed citations
20.
Fouqueray, Pascale, Xavier Leverve, Éric Fontaine, Mathurin Baquié, & Claes B. Wollheim. (2011). Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. Journal of Diabetes & Metabolism. 2(4). 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sébastien Bolze Breakdown of academic impact, for papers by Sophie Hallakou‐Bozec Breakdown of academic impact, for papers by Masanori Yokono Breakdown of academic impact, for papers by Rumi Kihara Breakdown of academic impact, for papers by Danielle Duffy Breakdown of academic impact, for papers by Jane Pinaire Breakdown of academic impact, for papers by G Lübben Breakdown of academic impact, for papers by Moira A. Clay Breakdown of academic impact, for papers by Hongwen Zhou Breakdown of academic impact, for papers by Richard L. Dunbar
Rankless by CCL
2026